Abstract
Coronary Heart Disease (CHD) remains a leading cause of global mortality. While lipid profiles are standard risk markers, the role of natural autoantibodies in cardiovascular health is an emerging field. This study identifies three novel autoantigens—G6PI, TPM1, and HnRNPDL—that are significantly elevated in CHD patients. Notably, lower levels of anti-TPM1 antibodies were found to correlate with higher total cholesterol and LDL levels, suggesting a protective role for these antibodies in vascular homeostasis.
Introduction
Predicting the progression of Coronary Heart Disease (CHD) requires a deeper understanding of the immune system's role in cardiovascular health. Autoantibodies, typically associated with autoimmune disorders, can play dual roles in CHD: some contribute to arterial damage, while others act as "natural" protectors by clearing cellular debris or modulating inflammation. This research aimed to identify novel autoantigens that could serve as biomarkers for CHD risk and provide insight into the immune-metabolic link.
Methodology
The study employed a multi-stage experimental design. Initially, a custom protein microarray containing 37 candidate autoantigens was developed to screen serum from a discovery cohort (20 CHD patients and 15 healthy controls). To ensure the reliability of this high-throughput screening, the researchers validated the microarray's reproducibility and quality.
Following the initial screening, the most promising "hits" were validated using Enzyme-Linked Immunosorbent Assays (ELISA) in a larger cohort of 262 individuals (131 CHD patients and 131 healthy controls). Statistical analyses were then performed to correlate antibody levels with clinical risk factors such as Total Cholesterol (TC) and Low-Density Lipoprotein (LDL).
Results
The screening process identified three novel CHD-associated autoantigens: glucose-6-phosphate isomerase (G6PI), alpha-tropomyosin (TPM1), and heterogeneous nuclear ribonucleoprotein D-like (HnRNPDL). These proteins were validated through SDS-PAGE and Mass Spectrometry to confirm their identity and purity before further testing.
ELISA results showed that all three autoantibodies were significantly higher in CHD patients compared to healthy controls (P < 0.0001). However, a critical finding emerged regarding TPM1: anti-TPM1 antibody levels showed a significant negative correlation with Total Cholesterol (P = 0.0034) and LDL Cholesterol (P = 0.0086). This inverse relationship suggests that while the antibodies are present in higher quantities in diseased states, lower relative levels within the patient group are associated with worse lipid profiles.
Discussion and Implications
The discovery of G6PI, TPM1, and HnRNPDL as novel biomarkers expands the known landscape of CHD immunology. The most significant insight is the "Natural Protector" hypothesis for anti-TPM1. Unlike typical disease markers where higher levels indicate greater severity, the negative correlation between anti-TPM1 and cholesterol suggests these antibodies may help maintain vascular health. A decline in these natural defenses could potentially accelerate the progression of atherosclerosis by failing to clear lipids or modulate arterial inflammation.
Conclusion
This study identifies G6PI, TPM1, and HnRNPDL as novel autoantigens in CHD. The association between low anti-TPM1 levels and increased lipid risk factors highlights its potential as a predictive marker for CHD complications. Future research should focus on larger, more diverse cohorts and functional studies to determine the exact mechanisms by which these antibodies influence arterial health.
Summary updated